Advance Pharmaceutical of Hong Kong completed enrollment for the clinical trial of BTI-320, also known as Sugardown® , at the Chinese University of Hong Kong (CUHK). The clinical trial enrolled 60 pre-diabetic patients and is a single-center, 16-week, randomized, double-blind pilot study designed to evaluate the efficacy and safety of BTI-320 in the treatment of high risk subjects with pre-diabetes. It is supplemental to an on-going separate clinical trial being conducted in mainland China.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
